Skip to main content
Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc. — Investor Relations & Filings

Ticker · TYRA ISIN · US90240B1061 US Professional, scientific and technical activities
Open in API
Filings indexed 369 across all filing types
Latest filing 2026-06-02 Declaration of Voting R…
Country US United States of America
Listing US TYRA

About Tyra Biosciences, Inc.

https://tyra.bio/

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines. The company specializes in therapies targeting fibroblast growth factor receptor (FGFR) biology, aiming to overcome tumor resistance and address key drivers of disease. Utilizing its proprietary SNÅP Discovery Engine, Tyra Biosciences designs innovative molecular structures. Its lead clinical program involves the development of oral dabogratinib for the treatment of skeletal dysplasia and urologic cancers.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a Form 8-K under Item 5.07 Submission of Matters to a Vote of Security Holders, detailing vote counts for director elections and ratification of auditors. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-06-02 English
10-Q - Tyra Biosciences, Inc. (0001863127) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
8-K - Tyra Biosciences, Inc. (0001863127) (Filer)
Earnings Release Classification · 94% confidence The document is a Form 8-K current report under Item 2.02 “Results of Operations and Financial Condition,” which attaches a press release announcing the company’s quarterly financial results for the quarter ended March 31, 2026. This corresponds to an initial announcement of periodical financial results, fitting the “Earnings Release (ER)” category. Q1 2026
2026-05-13 English
ARS - Tyra Biosciences, Inc. (0001863127) (Filer)
Annual Report
2026-04-17 English
DEF 14A - Tyra Biosciences, Inc. (0001863127) (Filer)
Proxy Solicitation & Information Statement
2026-04-17 English
8-K - Tyra Biosciences, Inc. (0001863127) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 16, 2026, by Tyra Biosciences, Inc. The content focuses on the appointment of a new director to the board, including biographical details, compensation, and board independence determination. There is no financial data or report content, but rather an announcement of a change in the company's board of directors. This matches the definition of Board/Management Information (MANG). The document length is about 5982 characters, which is sufficient to contain detailed information about the director appointment. Therefore, the classification is MANG with high confidence.
2026-04-17 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.